<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-154158</identifier>
<setSpec>2173-9218</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pneumococcal vaccination. Community pharmacy procedure</dc:title>
<dc:description xml:lang="en">SEFAC, semFYC, SEMERGEN and SEPAR were involved in the production of the document. The primary objective was to define the patient profiles most susceptible to be vaccinated against pneumococcus, considering the risk groups, the associated pathologies and the possible consequences of a pneumococcal infection and in turn, to develop a vaccination program in adults. The vaccine indications were also defined, as well as the proposed consultation by the community pharmacy. The document, backed by the main medico-pharmaceutical science companies, will be very useful to community pharmacies with regards to handling patients with a greater degree of risk of contracting pneumococcal disease. This will also be a very explicit way of detecting, assessing and, as necessary, diverting medical staff to this type of patients (AU)</dc:description>
<dc:creator>Casas Jansá, Ricard</dc:creator>
<dc:creator>Molina París, Jesús</dc:creator>
<dc:creator>Quintano Jiménez, José Antonio</dc:creator>
<dc:creator>Rodríguez González-Moro, José Miguel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En la elaboración del documento han participado SEFAC, semFYC, SEMERGEN y SEPAR. El objetivo principal era definir los perfiles de paciente susceptibles prioritariamente de la vacunación frente al neumococo considerando los grupos de riesgo, las patologías concomitantes, las posibles consecuencias de una infección neumocócica y la elaboración, a su vez, de un algoritmo de vacunación en el adulto. Se han definido igualmente las indicaciones de la vacuna así como la propuesta de entrevista por parte de la farmacia comunitaria. El documento, avalado por las principales sociedades científicas médico-farmacéuticas, será de gran utilidad para el farmacéutico comunitario de cara a abordar a pacientes con mayor factor de riesgo de contraer enfermedad neumocócica. Será también una manera muy gráfica para conseguir detectar, asesorar y, llegado el caso, derivar al facultativo médico a todo este tipo de paciente (AU)</dc:description>
<dc:source>Farm. comunitarios (Internet);8(2): 35-47, jun. 2016. ilus, tab, mapas, graf</dc:source>
<dc:identifier>ibc-154158</dc:identifier>
<dc:title xml:lang="es">Vacunación en neumococo. Actuación en la farmacia comunitaria</dc:title>
<dc:subject>^d29627</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33885^s22019</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d10785^s22048</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d10785^s22011</dc:subject>
<dc:subject>^d10785^s22055</dc:subject>
<dc:subject>^d11437^s22053</dc:subject>
<dc:subject>^d11437^s22012</dc:subject>
<dc:subject>^d30057^s22041</dc:subject>
<dc:subject>^d11437^s22044</dc:subject>
<dc:subject>^d11437^s22016</dc:subject>
<dc:subject>^d10785^s37748</dc:subject>
<dc:subject>^d33885^s22060</dc:subject>
<dc:subject>^d30057^s22011</dc:subject>
<dc:type>article</dc:type>
<dc:date>201606</dc:date>
</metadata>
</record>
</ibecs-document>
